ArticleHuman vaccines & immunotherapeutics2020
Promise and challenges in the development of COVID-19 vaccines.
Article in Human vaccines & immunotherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- The impact of educational interventions on COVID-19 and vaccination attitudes among patients in Michigan: A prospective study.Frontiers in public health · 2023Trial
- Beneath the rhetoric of global justice: Reinforcement of global hegemonic governmentality by South Korea's Global Vaccine Hub Project.Globalization and health · 2025Article
- A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting.Scientific reports · 2025Article
- Current Updates on Pathogenesis, Systemic Therapy, and Treatment of Invasive Fungal Infections.Current drug targets · 2025Review
- A Correlation Study to Comprehend the SAR-CoV-2 Viral Load, Antiviral Antibody Titer, and Severity of COVID-19 Symptoms Post-infection Amongst the Vaccinated Population in Kamrup District of As sam, Northeast India.Endocrine, metabolic & immune disorders drug targets · 2024Article
- CD4 + Count: a Variable to Be Considered to Prioritize COVID-19 Vaccination in PLHIV.Current pharmacology reports · 2023Review
- COVID-19 vaccination: Is it a matter of concern?Journal of family medicine and primary care · 2022Article
- Mind the "Vaccine Fatigue".Frontiers in immunology · 2022Review
- Roborovski hamsterVirulence · 2021Article
- Article
- Side Effects Following Administration of the First Dose of Oxford-AstraZeneca's Covishield Vaccine in Bangladesh: A Cross-Sectional Study.Infectious disease reports · 2021Article
- Public Knowledge, Attitude, and Perception towards COVID-19 Vaccination in Saudi Arabia.International journal of environmental research and public health · 2021Article
- Intranasal Vaccination Strategy to Control the COVID-19 Pandemic from a Veterinary Medicine Perspective.Animals : an open access journal from MDPI · 2021Article
- COVID-19 Vaccine Acceptance in Azuay Province, Ecuador: A Cross-Sectional Online Survey.Vaccines · 2021Article
- From Isolation to Containment: Perceived Fear of Infectivity and Protective Behavioral Changes during the COVID-19 Vaccination Campaign.International journal of environmental research and public health · 2021Article
- The landscape of antibody binding in SARS-CoV-2 infection.PLoS biology · 2021Article
- Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic.Immune network · 2021Review
- Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization.Pathogens (Basel, Switzerland) · 2021Review
- Correlation Between SARS-Cov-2 Vaccination, COVID-19 Incidence and Mortality: Tracking the Effect of Vaccination on Population Protection in Real Time.Frontiers in genetics · 2021Article
- Effect of a Concise Educational Program on COVID-19 Vaccination Attitudes.Frontiers in public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pandemic outbreak of COVID-19, caused by coronavirus SARS-CoV-2, created an unprecedented challenge to global public health system and biomedical community. Vaccination is an effective way to prevent viral infection, stop its transmission, and develop herd immunity. Rapid progress and advances have been made to date in the development of COVID-19 vaccines. Currently, more than 115 vaccine candidates have been developed from different technology platforms with several of them in clinical trials. Most of those vaccine candidates are developed based on the experience with other coronaviruses with an aim to induce neutralizing antibodies against the viral spike protein or its different receptor binding domains. Here, we discuss the promise, potential scientific challenges, and future directions for the development of a safe and effective COVID-19 vaccine. We also emphasize the importance of a better understanding of the infection pathogenesis and host defense mechanisms against SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.